Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor (FGF) receptors 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury. It is grouped under the following drug class(es): Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Balversa and erdafitinibum. Its PubChem CID is 67462786.
Erdafitinib
| CAS No | 1346242-81-6 |
|---|---|
| Molecular Formula | C25H30N6O2 |
| Molecular Weight | 446.5 g/mol |
| Synonyms | N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor (FGF) receptors 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma.
The listed CAS number is 1346242-81-6.
The listed molecular formula is C25H30N6O2.
The listed molecular weight is 446.5 g/mol.
N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine.
The source lists Balversa and erdafitinibum.